University College Dublin

Patrick Guiry

B Therese Kinsella

Helen Reid

Barry O'Connor

Catherine Godson

Claire Wilson

Kevin Gahan

Monica De Gaetano

Catherine Tighe

Eibhlin Butler

Denise Moran

Andrea Zanetti

Therese B Kinsella

The present invention relates to a compound of formula (I): wherein L is an optionally substituted heterocyclic group excluding unsubstituted monocyclic pyridine groups; wherein a is 0, 1 or 2; wherein Ris H or with Ris a bond; wherein Ris an optionally substituted alkoxy or aryloxy group, or with Rforms a bond; wherein Ris an optionally substituted alkyl group; and wherein Ris CH, CMeor O. Such compounds may be used in the treatment or prophylaxis of a disease or condition in which inhibition of acute inflammation and/or promotion of its resolution and/or suppression of fibrosis. 

Heterocyclic lipoxin analogs and uses thereof

The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TP&#x3b1;) or TPbeta (TP&#x3b2;) receptor subtype.

Thromboxane receptor antagonists

Growing community of inventors

Dublin, Ireland

Patrick Guiry